Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
History
Social responsibility
Our companies
Debiopharm Group
Debiopharm S.A.
Debio R.P. S.A.
Debioclinic S.A.
Debiovision Inc.
Debioinnovation S.A.
Business Model
Strengths
Development capabilites
Preclinical
Clinical
Manufacturing
Regulatory
Innovative drug delivery and formulation
Partnering
Licensing-in
Licensing-out
Partners
Pipeline
Commercial Products
Eloxatin®
Decapeptyl®
News & Events
Press Releases
Awards
Publications
Conferences
News
20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions
Home
News & Events
Press Releases
PRESS RELEASES
Order
Date asc
Date desc
Title asc
Title desc
Ordering
Display #
5
10
15
20
25
30
50
Date
Item Title
23-Jul-2003
H3 Pharma Inc. announces important step in bringing SANVAR® (vapreotide) to U.S. market
01-Jul-2003
H3 Pharma Inc. Licenses in Sanvar ® (vapreotide) from Debiopharm S.A.
09-Jan-2001
Swiss drug developer Debiopharm S.A. achieves another success in the development of molecules for theraeutic use
< Prev
1
2
Next >
Results 11 - 13 of 13
Debio 0827
( 1 items )
Debio 0826
( 1 items )
Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®
( 10 items )
Debio 025
( 5 items )
Debio 9902 - ZT-1
( 9 items )
Debio 0614 (istaroxime)
( 2 items )
Debio 0507
( 3 items )
Debio 0719
( 1 items )
Debio 0617
( 2 items )
Oxaliplatin – Eloxatin® – Elplat®
( 10 items )
Moapar® - Salvacyl®
( 3 items )
Other News
( 47 items )
